Listing 1 - 10 of 10 |
Sort by
|
Choose an application
In samenwerking met de afdeling Psychiatrie van de University of Arizona College of Medecine werd op 16 en 17 november 1977 door de Roche Laboratoria van de Verenigde Staten een eerste belangrijk symposium georganiseerd met als thema "Angst bij bejaarden". De tekst van deze brochure bevat twee van de thema's die tijdens dit symposium werden behandeld, thema's die artsen van alle disciplines aanbelangen. De folder is fraai geïllustreerd met de portretten van Felix De Boeck die we zo goed kennen. Niet verwonderlijk natuurlijk dat Roche ook zijn eigen producten in de kijker zet: de namen Lexotan en Valium klinken ons heel vertrouwd in de oren.
Choose an application
Choose an application
This edition of the Annual Review of Gerontology and Geriatrics brings together, in one convenient volume, the results of many of the studies supported by the Hartford Foundation. The first two chapters of this volume set the stage for the specific research reports that follow. In the first chapter, Burke, Jolson, Goetsch, and Ahronheim review current information on medication use and the adverse drug events in the elderly from two national data bases: The National Disease and Therapeutic Index and the Food and Drug Administration's Spontaneous Reporting System. The second chapters present the
Chemotherapy. --- Older people --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Pharmacology --- Diseases --- Treatment. --- Medical care.
Choose an application
Choose an application
Geriatrics --- Health --- Aged --- Geriatrics
Choose an application
Choose an application
Choose an application
"Advances in human genetics have begun to yield clinical benefits through the development of Precision Medicine (PM). The benefits of this innovation are promising, both through application of constitutional genetics detecting mutations that affect the risk of disease and tumor genetics, and malignancy-causing mutations susceptible to targeted therapies. While PM may ultimately be used in all aspects of medicine, to date, the most fruitful applications have been in maternal-fetal medicine and cancer. However, due to the complexity and cost of developing these innovations, and to privacy issues, advancing PM is a challenge in traditional clinical, reimbursement, and regulatory landscapes. Although much of the literature focuses on challenges in relating constellations of mutations to the identification of actual current or potential disease states, and to the efficacy of treatments, diffusion of PM also depends on many non-clinical factors. For example, how will information on accurate diagnosis and treatment success be disseminated, and who will bear the cost? How might physician training change to incorporate genetic, probability, statistics, and economic considerations? How can patients reconcile with the ethical and privacy concerns related to the availability of genetic information? Will the era of PM yield still more disparities in access to care? Will cost-effectiveness analysis need to change to better take into account patient heterogeneity? This volume explores the intersection of the scientific, clinical, and economic factors to consider in developing PM. We explore the theoretical and historical underpinnings of PM, discuss implementation issues, and present examples of real-world applications."--
Pharmacogenetics --- Personalized medicine --- Precision Medicine --- Pharmacogenetics
Choose an application
Choose an application
Listing 1 - 10 of 10 |
Sort by
|